IQV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 37 cases where IQV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Following a +3.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 190 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 102 of 223 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 46%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IQV as a result. In 54 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. IQV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.092) is normal, around the industry mean (63.909). P/E Ratio (32.744) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
It is expected that a price bounce should occur soon.
Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMTI advanced for three days, in 191 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
SMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 191 cases where SMTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 56 cases where SMTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMTI as a result. In 61 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
SMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMTI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SMTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SMTI's P/B Ratio (38.332) is very high in comparison to the industry average of (4.887). P/E Ratio (-8.909) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (2.050) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (2.777) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IQV | SMTI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 94 | 96 | |
SMR RATING 1..100 | 43 | 99 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 27 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IQV's Valuation (72) in the Servicestothe Health Industry industry is in the same range as SMTI (81) in the null industry. This means that IQV’s stock grew similarly to SMTI’s over the last 12 months.
IQV's Profit vs Risk Rating (94) in the Servicestothe Health Industry industry is in the same range as SMTI (96) in the null industry. This means that IQV’s stock grew similarly to SMTI’s over the last 12 months.
IQV's SMR Rating (43) in the Servicestothe Health Industry industry is somewhat better than the same rating for SMTI (99) in the null industry. This means that IQV’s stock grew somewhat faster than SMTI’s over the last 12 months.
IQV's Price Growth Rating (50) in the Servicestothe Health Industry industry is in the same range as SMTI (50) in the null industry. This means that IQV’s stock grew similarly to SMTI’s over the last 12 months.
IQV's P/E Growth Rating (27) in the Servicestothe Health Industry industry is significantly better than the same rating for SMTI (97) in the null industry. This means that IQV’s stock grew significantly faster than SMTI’s over the last 12 months.
| IQV | SMTI | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 77% |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 79% |
| Advances ODDS (%) | 6 days ago 62% | 9 days ago 75% |
| Declines ODDS (%) | 2 days ago 64% | 2 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 46% | 2 days ago 65% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 1 FA rating(s) are green while SMTI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 3 TA indicator(s) are bullish while SMTI’s TA Score has 4 bullish TA indicator(s).
IQV (@Medical Specialties) experienced а +1.40% price change this week, while SMTI (@Pharmaceuticals: Other) price change was -5.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.54%. For the same industry, the average monthly price growth was -5.47%, and the average quarterly price growth was +43.18%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.91%. For the same industry, the average monthly price growth was -2.49%, and the average quarterly price growth was +7.66%.
IQV is expected to report earnings on Oct 27, 2026.
SMTI is expected to report earnings on Nov 16, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+0.91% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SOXL | 98.65 | 4.98 | +5.32% |
| Direxion Daily Semiconductor Bull 3X ETF (SOXL) | |||
| PCLN | 29.42 | 0.15 | +0.53% |
| Pictet Cleaner Planet ETF (PCLN) | |||
| NBCR | 34.26 | 0.15 | +0.44% |
| Neuberger Core Equity ETF (NBCR) | |||
| JOET | 45.06 | 0.05 | +0.11% |
| Virtus Terranova U.S. Quality Momentum ETF (JOET) | |||
| LENS | 43.88 | -0.12 | -0.27% |
| Sarmaya Thematic ETF (LENS) | |||
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | -0.38% | ||
| CRL - IQV | 71% Closely correlated | -0.04% | ||
| TMO - IQV | 68% Closely correlated | -1.54% | ||
| RVTY - IQV | 59% Loosely correlated | -1.11% | ||
| A - IQV | 58% Loosely correlated | -1.77% | ||
| ICLR - IQV | 54% Loosely correlated | -1.20% | ||
More | ||||